| Latest Peregrine Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 08/11/2008 | 8:00AM | PRNUS | Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- Peregrine Achieves Milestone as Third Phase II Trial in Its Bavituximab Cancer Program Begins Patient Enrollment and Dosing -
TUSTIN, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate... More...>> |
| 07/23/2008 | 4:05PM | PRNUS | Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
- Company Will Request Hearing to Present Plans for Regaining Compliance -
TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), today announced that it received a Staff Determination letter from the Nasdaq Stock Market (NASDAQ) on July 22, 2008 indicating that the company... More...>> |
| 07/14/2008 | 7:00AM | PRNUS | Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
- Achieves Record Revenues While Advancing Three Major Clinical Programs and Securing 5-Year Contract With U.S. Defense Threat Reduction Agency Worth Up to $44.4 Million -
TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), today announced financial results for fiscal year... More...>> |
| 07/09/2008 | 9:00AM | PRNUS | Peregrine Pharmaceuticals to Report Fiscal Year 2008 Financial Results
TUSTIN, Calif., July 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced that it will release its fiscal year 2008 financial results on July 14, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.
Peregrine's... More...>> |
| 07/02/2008 | 9:30AM | PRNUS | Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
- Pre-Specified Primary Efficacy Endpoint Met in Stage 1 of Two-Stage Study -
TUSTIN, Calif., July 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical... More...>> |
| 07/01/2008 | 7:50AM | PRNUS | Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
- Five-Year Defense Threat Reduction Agency Contract Will Support Development of Bavituximab and Fully Human Equivalent as Potential Broad-Spectrum Anti-Viral Agents -
TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing... More...>> |
| 06/30/2008 | 8:00AM | PRNUS | Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
-- Peregrine's Second Phase II Bavituximab Cancer Trial Is Evaluating the Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and Paclitaxel --
TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced that patient screening and dosing has begun in... More...>> |
| 06/25/2008 | 1:45AM | PRNUS | DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell
LEIDEN, Netherlands and PARSIPPANY, N.J., June 25 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Avid Bioservices, Inc. of Tustin, California to join their Vendor Network. Under the terms of the agreement, Avid... More...>> |
| 06/16/2008 | 7:45AM | PRNUS | Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
- New Claims Cover Anti-Viral Applications of Novel Targeted Agents Under the Company's Anti-Phospholipid Technology Platform -
TUSTIN, Calif., June 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment... More...>> |
| 06/02/2008 | 7:30AM | PRNUS | Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breas
- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable Disease -
CHICAGO and TUSTIN, Calif., June 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today announced that results from a Phase I clinical... More...>> |
| 05/31/2008 | 7:30AM | PRNUS | Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
-Study Results Show 100-Fold More Radiation Delivered to Tumor as Compared to Other Organs-
CHICAGO and TUSTIN, Calif., May 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today reported that clinical researchers from the Abramson Cancer Center of the University of Pennsylvania will present... More...>> |
| 05/13/2008 | 10:00AM | PRNUS | Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infectio
- Two New Studies Provide Further Evidence that PS Plays a Critical Role in Some Viral Infections -
TUSTIN, Calif., May 13 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus... More...>> |
| 04/29/2008 | 9:00AM | PRNUS | Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
- First 15 Patients Are Enrolled and Dosing With Bavituximab Plus Docetaxel Combination Regimen is Underway -
TUSTIN, Calif., April 29 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis... More...>> |
| 04/15/2008 | 11:00AM | PRNUS | Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
- Bavituximab Causes Pro-Inflammatory Effects in the Tumor Microenvironment That May Contribute to Its Anti-Tumor Efficacy -
SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) today reported that preclinical studies being presented at the 2008 Annual Meeting... More...>> |
| 04/15/2008 | 8:45AM | PRNUS | Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Resp
- 80% of Subjects Immunized with Anti-PS Immunocytokines and Irradiated Tumor Cells Achieved Long-Term Survival Compared to Just 20% of Controls -
SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) reported that a preclinical study presented yesterday at the... More...>> |
| 04/15/2008 | 7:45AM | PRNUS | Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Me
-No Metastatic Lesions Were Detectable After Combination Therapy Treatment-
SAN DIEGO and TUSTIN, Calif., April 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C... More...>> |
| 04/14/2008 | 11:00AM | PRNUS | Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting A
-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical Breast Cancer Models-
SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced today that a preclinical... More...>> |
| 04/11/2008 | 8:00AM | PRNUS | Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meet
TUSTIN, Calif., April 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of... More...>> |
| 03/11/2008 | 7:00AM | PRNUS | Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
-Advances Reported in All Three Clinical Programs, Including Launch of Key Bavituximab Phase II Cancer Program-
TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and... More...>> |
| 03/11/2008 | 7:00AM | PRNUS | Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
- Cotara(R) Appears Safe and Well Tolerated in Dosimetry and Phase II Trials, with Some Patients Already Past the Expected Median Average Survival Time for This Population - - Data From Dosimetry Trial Accepted for Presentation at 2008 ASCO Annual Meeting -
TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine... More...>> |